Mar 31, 2021 6:30am EDT BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Mar 24, 2021 6:30am EDT BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021
Mar 02, 2021 7:00am EST BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
Feb 02, 2021 6:30am EST BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy
Dec 09, 2020 4:30pm EST BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer
Nov 16, 2020 6:30am EST BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
Nov 12, 2020 6:30am EST BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates
